ArticleThe New England journal of medicine2013
TREM2 and neurodegenerative disease.
Article in The New England journal of medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Convergent Genetic and Expression Datasets Highlight TREM2 in Parkinson's Disease Susceptibility.Molecular neurobiology · 2016Pooled it
- The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2015Pooled it
- Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease.Pharmacology research & perspectives · 2019Trial
- High-Throughput Screening and Initial SAR Studies Identify a Novel Submicromolar Potent Human cGAS Inhibitor.ACS chemical biology · 2025Article
- The late-onset Alzheimer's disease risk factor RHBDF2 is a modifier of microglial TREM2 proteolysis.Life science alliance · 2025Article
- TREM-2 Drives Development of Multiple Sclerosis by Promoting Pathogenic Th17 Polarization.Neuroscience bulletin · 2024Article
- Overlapping Neuroimmune Mechanisms and Therapeutic Targets in Neurodegenerative Disorders.Biomedicines · 2023Review
- Pathogenesis of Alzheimer's disease: Involvement of the choroid plexus.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- TREM2 mediates physical exercise-promoted neural functional recovery in rats with ischemic stroke via microglia-promoted white matter repair.Journal of neuroinflammation · 2023Article
- Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology.Molecular neurodegeneration · 2023Article
- Friend turned foe: TREM2 agonist in battles against tau.The Journal of experimental medicine · 2023Article
- Inflammation in obesity, diabetes, and related disorders.Immunity · 2022Review
- Sex Differences in Neurodegeneration: The Role of the Immune System in Humans.Biological psychiatry · 2022Review
- AD-linked R47H-Science translational medicine · 2021Article
- Presenilin 1 phosphorylation regulates amyloid-β degradation by microglia.Molecular psychiatry · 2021Article
- Impaired Iron Homeostasis and Haematopoiesis Impacts Inflammation in the Ageing Process in Down Syndrome Dementia.Journal of clinical medicine · 2021Article
- Origins, Biology, and Diseases of Tissue Macrophages.Annual review of immunology · 2021Review
- Cerebral sterile inflammation in neurodegenerative diseases.Inflammation and regeneration · 2020Review
- γ-Secretase cleavage of the Alzheimer risk factor TREM2 is determined by its intrinsic structural dynamics.The EMBO journal · 2020Article
- Review
Corrections and comments
- Comment on
- Comment on
- Comment on
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
24131183What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.